


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/939,230
				Filing Date	August 24, 2001
				First Named Inventor	Wickenden, Alan David
				Art Unit	1614
				Examiner Name	Royds, Leslie A.
Sheet	1	of	2	Attorney Docket Number	018512-006610US

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number Kind Code ² (if known)				
LAR	1.	US-5,466,698-A	11-14-1995	Glase et al.		
LAR	2.	US-6,326,385-B1	12-04-2001	Wickenden et al.		
LAR	3.	US-6,372,767-B1	04-18-2002	McNaughton-Smith et al.		
LAR	4.	US-6,605,725-B2	08-12-2003	McNaughton-Smith et al.		
LAR	5.	US-6,989,398-B2	01-24-2006	McNaughton-Smith et al.		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
LAR	6.	DE	2 343 787	A	03-21-1974	Sterling Drug, Inc.	Translation of Abstract Only	<input type="checkbox"/>
LAR	7.	DE	33 05 569	A1	08-23-1984	Bayer AG	Translation of Abstract Only	<input type="checkbox"/>
LAR	8.	DE	38 04 346	A1	08-24-1989	Boehringer Mannheim GmbH	Translation of Abstract Only	<input type="checkbox"/>
LAR	9.	EP	0 882 726	A1	12-09-1998	Eli Lilly and Company		<input type="checkbox"/>
LAR	10.	JP	57-131719	A	08-14-1982	Chugai Pharmaceutical Co., Ltd.	Translation of Abstract Only	<input type="checkbox"/>
LAR	11.	JP	57-206661	A	12-18-1982	Chugai Pharmaceutical Co. Ltd.	Translation of Abstract Only	<input type="checkbox"/>
LAR	12.	JP	58-089812	A	04-26-1983	Chugai Pharmaceutical Co., Ltd.	Translation of Abstract Only	<input type="checkbox"/>
LAR	13.	JP	59-175467	A	10-04-1984	Chugai Pharmaceutical Co., Ltd.	Translation of Abstract Only	<input type="checkbox"/>
LAR	14.	JP	59-181257	A	10-15-1984	Chugai Pharmaceutical Co. Ltd.	Translation of Abstract Only	<input type="checkbox"/>
LAR	15.	JP	08-176113		07-09-1996	Dainippon Pharmaceutical Co., Ltd.	Translation of Abstract Only	<input type="checkbox"/>
LAR	16.	JP	10-259176	A	09-29-1998	Japan Tobacco, Inc.	Translation of Abstract Only	<input type="checkbox"/>
LAR	17.	WO	98/42672	A1	10-01-1998	Kyowa Hakko Kogyo Co., Ltd.	Translation of Abstract Only	<input type="checkbox"/>
LAR	18.	WO	99/05113	A1	02-04-1999	BYK Gulden Lomberg Chemische Fabrik GmbH		<input type="checkbox"/>
LAR	19.	WO	01/10380	A2, A3	02-15-2001	Icagen, Inc.		<input type="checkbox"/>
LAR	20.	WO	01/21596	A1	03-29-2001	Astrazeneca AB		<input type="checkbox"/>
LAR	21.	WO	01/55115	A1	08-02-2001	Cytovia, Inc.		<input type="checkbox"/>
LAR	22.	WO	03/004467	A2, A3	01-16-2003	Agouron Pharmaceuticals, Inc.		<input type="checkbox"/>
LAR	23.	WO	03/020722	A1	03-13-2003	Boehringer Ingelheim Pharma KG	Translation of Abstract Only	<input type="checkbox"/>

Examiner Signature		Date Considered	12 DEC 01
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/939,230
		Filing Date	August 24, 2001
		First Named Inventor	Wickenden, Alan David
		Art Unit	1614
Examiner Name	Royds, Leslie A.		
Attorney Docket Number	018512-006610US		
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
WAR	24.	Arakida, Y. et al. "Binding of YM158, A New Dual Antagonist for Leukotriene D ₄ and Thromboxane A ₂ Receptors, to Guinea Pig Lung Membranes," <i>European Journal of Pharmacology</i> 1998, Vol. 362, pp. 229-233.	<input type="checkbox"/>
WAR	25.	Proudfoot, J.R. et al. "A Novel Smiles Rearrangement Gives Access to the A-Ring Pyridine Isomers of the Nevirapine Ring System," <i>Journal of Organic Chemistry</i> 1993, Vol. 58, No. 25, pp. 6996-7000.	<input type="checkbox"/>
WAR	26.	Sawanishi, H. et al. "Studies on Diazepines. XXVI. Synthesis of 6H-1, 4-Diazepines and 1-Acyl-1H-1, 4-diazepines from 4-Pyridyl Azides," <i>Chemical Pharmaceutical Bulletin</i> 1987, Vol. 35, No. 8, pp. 3175-3181.	<input type="checkbox"/>
WAR	27.	Seidel, M.C. et al. "Reactions of 2-Acetoacetylaminopyridines with Triethyl Orthoformate and Zinc Chloride," <i>The Journal of Organic Chemistry</i> May 1970, Vol. 53, No. 5, pp. 1475-1480.	<input type="checkbox"/>

Examiner Signature		Date Considered	12 DEC 01
--------------------	---	-----------------	-----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.